Javascript must be enabled to continue!
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
View through CrossRef
Abstract
Semaglutide is often optimized for weight loss, but whether longer-term cardiovascular benefit tracks achieved weight loss or therapeutic exposure levels remains unclear. We conducted a retrospective observational study using a federated, deidentified U.S. electronic health record network and applied multimodal AI-based methods to analyze 47,199 patients with baseline cardiovascular disease. We quantified dose escalation and weight change during the 0–2-year period after semaglutide initiation (landmark period) and assessed cardiovascular outcomes during the 2–4-year period (post-landmark). To mitigate confounding, we performed propensity-matched comparisons during the landmark period, in which semaglutide was associated with lower rates of cardiovascular events than metformin, DPP-4 inhibitors, and SGLT2 inhibitors; however, these findings should be interpreted as associative and remain susceptible to treatment selection bias. Higher maximum semaglutide dose was associated with greater weight loss during the landmark period (3.15% additional weight loss per 1 mg increase; r = − 0.97, P < 0.001) and with lower post-landmark risk of all-cause mortality (RR 0.42, P < 0.001), composite cardiovascular events (death, myocardial infarction, or stroke; RR 0.51, P < 0.001), cerebrovascular disease (RR 0.50, P < 0.001), heart failure (RR 0.55, P < 0.001), and valvular or rheumatic heart disease (RR 0.71, P = 0.025), providing robust associative evidence that supports prospective evaluation of causal relationships. In contrast, greater achieved weight loss during the landmark period did not show a consistent monotonic association with lower post-landmark cardiovascular risk (All-cause mortality p-value = 0.14, composite cardiovascular endpoint p-value = 0.55). Integrating insights from a single cell GLP1R expression atlas was used to infer how semaglutide pharmacology may tie into heart-specific signaling, beyond what is reflected by body-weight reduction alone. The strongest prevalence-weighted GLP1R signal was observed in the pancreas, followed by the heart, where GLP1R engagement potential (GEP) was considerable across cardiomyocyte, cardiac endothelial, and rarer immune cell populations. Together, in this retrospective observational study, semaglutide-associated cardiovascular benefit appears more closely aligned with maximum dose attained than with achieved weight-loss magnitude, supporting prospective validation and motivating beyond-obesity trial designs that integrate whole-body spatial intelligence.
Springer Science and Business Media LLC
Title: Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Description:
Abstract
Semaglutide is often optimized for weight loss, but whether longer-term cardiovascular benefit tracks achieved weight loss or therapeutic exposure levels remains unclear.
We conducted a retrospective observational study using a federated, deidentified U.
S.
electronic health record network and applied multimodal AI-based methods to analyze 47,199 patients with baseline cardiovascular disease.
We quantified dose escalation and weight change during the 0–2-year period after semaglutide initiation (landmark period) and assessed cardiovascular outcomes during the 2–4-year period (post-landmark).
To mitigate confounding, we performed propensity-matched comparisons during the landmark period, in which semaglutide was associated with lower rates of cardiovascular events than metformin, DPP-4 inhibitors, and SGLT2 inhibitors; however, these findings should be interpreted as associative and remain susceptible to treatment selection bias.
Higher maximum semaglutide dose was associated with greater weight loss during the landmark period (3.
15% additional weight loss per 1 mg increase; r = − 0.
97, P < 0.
001) and with lower post-landmark risk of all-cause mortality (RR 0.
42, P < 0.
001), composite cardiovascular events (death, myocardial infarction, or stroke; RR 0.
51, P < 0.
001), cerebrovascular disease (RR 0.
50, P < 0.
001), heart failure (RR 0.
55, P < 0.
001), and valvular or rheumatic heart disease (RR 0.
71, P = 0.
025), providing robust associative evidence that supports prospective evaluation of causal relationships.
In contrast, greater achieved weight loss during the landmark period did not show a consistent monotonic association with lower post-landmark cardiovascular risk (All-cause mortality p-value = 0.
14, composite cardiovascular endpoint p-value = 0.
55).
Integrating insights from a single cell GLP1R expression atlas was used to infer how semaglutide pharmacology may tie into heart-specific signaling, beyond what is reflected by body-weight reduction alone.
The strongest prevalence-weighted GLP1R signal was observed in the pancreas, followed by the heart, where GLP1R engagement potential (GEP) was considerable across cardiomyocyte, cardiac endothelial, and rarer immune cell populations.
Together, in this retrospective observational study, semaglutide-associated cardiovascular benefit appears more closely aligned with maximum dose attained than with achieved weight-loss magnitude, supporting prospective validation and motivating beyond-obesity trial designs that integrate whole-body spatial intelligence.
Related Results
=== PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === Knowledge of the Problem and Intention to Act on Student Environmentally Responsible Behavior
=== PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === === PAPER RETRACTED === Knowledge of the Problem and Intention to Act on Student Environmentally Responsible Behavior
<p><span lang="IN"><span style="vertical-align: inherit;"><span style="vertical-align: inherit;">=== PAPER RETRACTED === </span></span></span...
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED]Prima Weight Loss Dragons Den UK :-Obesity is a not kidding medical issue brought about by devouring an excessive amount of fat, eating terrible food sources, and practi...
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED]Prima Weight Loss Dragons Den UK :-Obesity is a not kidding medical issue brought about by devouring an excessive amount of fat, eating terrible food sources, and practi...
RANCANG BANGUN APLIKASI PENGENALAN BUDAYA WAKATOBI BERBASIS ANDROID
RANCANG BANGUN APLIKASI PENGENALAN BUDAYA WAKATOBI BERBASIS ANDROID
<p><em><span style="vertical-align: inherit;"><span style="vertical-align: inherit;"><span style="vertical-align: inherit;"><span style="vertical-a...
#3691 Successful use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in a patient with obesity and diabetic kidney disease under peritoneal dialysis: a Case Report
#3691 Successful use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in a patient with obesity and diabetic kidney disease under peritoneal dialysis: a Case Report
Abstract
Background
Semaglutide is a glucagon-like peptide-1 receptor agonists (GLP1-RA), which showed a significant effe...
Safety of Semaglutide
Safety of Semaglutide
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutan...
The craze with Semaglutide
The craze with Semaglutide
Semaglutide (Ozempic acid) belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications mimic the action of a hormone called GLP-1, which...
The craze with semaglutide
The craze with semaglutide
Semaglutide (Ozempic acid) belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications mimic the action of a hormone called GLP-1, which...

